1. Academic Validation
  2. Discovery of Potent, Selective, and Brain-Penetrant Small Molecule CD38 Inhibitors

Discovery of Potent, Selective, and Brain-Penetrant Small Molecule CD38 Inhibitors

  • ACS Med Chem Lett. 2026 Jan 29;17(2):259-265. doi: 10.1021/acsmedchemlett.5c00727.
Andrew J Stott 1 Roland W Bürli 1 Kevin J Doyle 1 Louise Dickson 1 Richard C Hewer 1 Philip Pickford 1 Maxine J Roberts 1 Rosie Waters-Hall 1 Yiming Wu 2 Matthias Zebisch 3 Victor Rangel 3 Matthis Geitmann 4 Kim Matthews 1 Nicola L Brice 1 Mark Carlton 1 Lee A Dawson 1 Jenna R M Harvey 1
Affiliations

Affiliations

  • 1 Cerevance Limited, 418 Cambridge Science Park, Cambridge CB4 0PZ, U.K.
  • 2 WuXi Apptec Co., Ltd., 288 Fute Zhong Rd., Waigaoqiao, Shanghai 200131, P. R. China.
  • 3 Evotec (U.K.) Ltd., 95 Park Drive Milton Park, Abingdon OX14 4RY, U.K.
  • 4 Beactica Therapeutics AB, Virdings allé, SE-754 50 Uppsala, Sweden.
Abstract

Cluster of differentiation 38 (CD38) is a nicotinamide adenine dinucleotide (NAD+)-consuming ectoenzyme abundantly expressed in brain regions involved in motor control and cognition. Given the central role of NAD+ in maintaining neuronal health, inhibition of CD38, resulting in NAD+ elevation, has emerged as a potential therapeutic approach for neurodegenerative diseases and age-associated cognitive decline. Herein, we report the rational, structure-guided optimization of a series of small-molecule CD38 inhibitors, culminating in the identification of CVN14, a potent, selective, and brain-penetrant tool molecule with favorable pharmacokinetic properties for advanced preclinical evaluation. We further disclose the first high-resolution X-ray crystal structure of the CVN14-ADPR-CD38 complex, revealing an uncompetitive binding mode. CVN14 provides a molecular tool to investigate CD38 biology in neurodegeneration and supports the development of next-generation brain-penetrant CD38 inhibitors.

Keywords

CD38; NAD+; neurodegeneration; small molecule inhibitor.

Figures
Products